CHRM5
Muscarinic acetylcholine receptor M5
As of the edition of 20 October 2026, CHRM5 (muscarinic acetylcholine receptor M5, UniProt P08912) has 6 drugs tested at it and 21 companies on the list, 2 on route A and 3 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P08912
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 2
- Disease areas
- Lungs and airways; Skin and connective tissue; Immune system; Nervous system; Digestive system; Infections; Heart and blood vessels; Pregnancy and women's health
- Registered trials of its drugs
- 164
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Went quiet | 3 |
| Withdrawn from market | 1 |
| Total | 6 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Glycopyrronium | Marketed | Phase 4 | none listed |
| Darotropium | Went quiet | Phase 2 | none listed |
| Sofpironium | Marketed | Phase 3 | Ends 2040 |
| PT010 | Went quiet | Phase 1 | none listed |
| Afacifenacin | Went quiet | Phase 2 | none listed |
| Terodiline | Withdrawn from market | No phase stated | none listed |
6 of 6 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Route B | 3 |
| Engaged | 14 |
| Undetermined | 2 |
| Total on the list | 21 |
| Company | Route |
|---|---|
| Botanix Sb | Route B |
| GSK | Route A |
| AstraZeneca | Route B |
The other 18 companies at CHRM5
In the product21 companies in all; 18 are not named here, and no score is.
See the 21 companies at CHRM5, ranked, with the facts behind eachRequest access. Nothing is shown until you do.